

CELL THERAPEUTICS INC  
Form 8-K  
July 14, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report: (Date of earliest event reported): July 10, 2006

**CELL THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

<b>Washington</b> (State or other jurisdiction of incorporation or organization)	<b>001-12465</b> (Commission File Number)	<b>91-1533912</b> (I.R.S. Employer Identification Number)
	<b>501 Elliott Avenue West, Suite 400</b> <b>Seattle, Washington 98119</b> (Address of principal executive offices)	

Registrant's telephone number, including area code: (206) 282-7100

**Not applicable**

(Former name or former address, if changed since last report).

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

## Edgar Filing: CELL THERAPEUTICS INC - Form 8-K

- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01. Entry into a Material Definitive Agreement.**

On July 10, 2006, the Compensation Committee (the "Committee") of Cell Therapeutics, Inc. (the "Corporation") authorized the payment of a bonus of \$169,952 to James A. Bianco, M.D., the Corporation's President and Chief Executive Officer. The Committee also authorized the payment of a contingent bonus of \$169,952 to Dr. Bianco payable if the Corporation achieves, on or before September 30, 2006, its long-standing corporate objective of closing a material collaboration transaction with a pharmaceutical company, subject to certain conditions.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELL THERAPEUTICS, INC.

Date: July 14, 2006

By: /s/ James A. Bianco  
James A. Bianco, M.D.  
President and Chief Executive Officer

-2-